| Autor: |
Saim Sağ, Aysel Aydin Kaderli, Abdülmecit Yildiz, Bülent Cuma Gül, Bülent Özdemir, Ibrahim Baran, Sümeyye Güllülü, Ali Aydınlar, Yüksel Çavuşoğlu |
| Jazyk: |
English<br />Turkish |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Türk Kardiyoloji Derneği Arşivi, Vol 45, Iss 5, Pp 415-425 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
1016-5169 |
| DOI: |
10.5543/tkda.2017.80026 |
| Popis: |
Objective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice. Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic patients admitted to our clinic due to deterioration of HF and having hyponatremia resistant to standard therapy. Severe hyponatremia was defined as serum sodium concentration ≤125 mEq/L. The database included demographic, clinical, laboratory, and echocardiographic findings on admission, and numerous outcome measures for oral tolvaptan treatment were used to assess its efficacy and safety. Results: The study group consisted of 56 hypervolemic HF patients with severe hyponatremia (25 female and 31 male) with mean age of 66 years. All patients received a single dose of tolvaptan 15 mg daily for an average of 3.2 days due to severe hyponatremia. Sodium and potassium concentrations, fluid intake, and urine volume increased (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
